These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 6631718)
41. Direct measurement of propranolol bioavailability during accumulation to steady-state. Wood AJ; Carr K; Vestal RE; Belcher S; Wilkinson GR; Shand DG Br J Clin Pharmacol; 1978 Oct; 6(4):345-50. PubMed ID: 698031 [TBL] [Abstract][Full Text] [Related]
42. Stereoselective hydrolysis of O-isovaleryl propranolol and its influence on the clearance of propranolol after oral administration. Shameem M; Imai T; Yoshigae Y; Sparreboom A; Otagiri M J Pharm Sci; 1994 Dec; 83(12):1754-7. PubMed ID: 7891307 [TBL] [Abstract][Full Text] [Related]
43. Effects of chlorpromazine on the disposition and beta-adrenergic blocking activity of propranolol in the dog. Bai SA; Abramson FP J Pharmacokinet Biopharm; 1984 Jun; 12(3):333-49. PubMed ID: 6502474 [TBL] [Abstract][Full Text] [Related]
44. Decreased absorption as a possible cause for the lower bioavailability of a sustained-release propranolol. Takahashi H; Ogata H; Warabioka R; Kashiwada K; Ohira M; Someya K J Pharm Sci; 1990 Mar; 79(3):212-5. PubMed ID: 2338628 [TBL] [Abstract][Full Text] [Related]
45. Stereoselective increase of plasma concentrations of the enantiomers of propranolol and atenolol during exercise. Stoschitzky K; Kahr S; Donnerer J; Schumacher M; Luha O; Maier R; Klein W; Lindner W Clin Pharmacol Ther; 1995 May; 57(5):543-51. PubMed ID: 7768077 [TBL] [Abstract][Full Text] [Related]
46. Single dose pharmacokinetics of (S)-atenolol administered orally as a single enantiomer formulation and as a racemic mixture (Tenormin). Clementi WA; Garvey TQ; Clifton GD; McCoy RA; Brandt S; Schwartz S Chirality; 1994; 6(3):169-74. PubMed ID: 8024947 [TBL] [Abstract][Full Text] [Related]
47. Lack of gastrointestinal metabolism of propranolol in dogs after portacaval transposition. Lo MW; Effeney DJ; Pond SM; Silber BM; Riegelman S J Pharmacol Exp Ther; 1982 May; 221(2):512-5. PubMed ID: 7077541 [TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetic-stereoselective differentiation of some isomeric analogues of ifosfamide. Sloderbach A; Hładoń B; Sochacki M; Kinas R; Kuśnierczyk H; Laskowska H Pol J Pharmacol; 1997; 49(6):463-9. PubMed ID: 9566050 [TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetics of clinafloxacin enantiomers in humans. Humphrey GH; Shapiro MA; Randinitis EJ; Guttendorf RJ; Brodfuehrer JI J Clin Pharmacol; 1999 Nov; 39(11):1143-50. PubMed ID: 10579144 [TBL] [Abstract][Full Text] [Related]
50. Stereoselective pharmacokinetic analysis of tramadol and its main phase I metabolites in healthy subjects after intravenous and oral administration of racemic tramadol. García Quetglas E; Azanza JR; Cardenas E; Sádaba B; Campanero MA Biopharm Drug Dispos; 2007 Jan; 28(1):19-33. PubMed ID: 17061296 [TBL] [Abstract][Full Text] [Related]
51. Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: major role of CYP3A. Desta Z; Soukhova N; Morocho AM; Flockhart DA J Pharmacol Exp Ther; 2001 Aug; 298(2):508-20. PubMed ID: 11454912 [TBL] [Abstract][Full Text] [Related]
52. The effect of ageing on the hepatic clearance of propranolol. Castleden CM; George CF Br J Clin Pharmacol; 1979 Jan; 7(1):49-54. PubMed ID: 760742 [TBL] [Abstract][Full Text] [Related]
53. (S)-4'-hydroxypropranolol causes product inhibition and dose-dependent bioavailability of propranolol enantiomers in the isolated perfused rat liver and in rat liver microsomes. Nand RA; Ghabrial H; Smallwood RA; Morgan DJ Xenobiotica; 1996 Dec; 26(12):1249-61. PubMed ID: 9004455 [TBL] [Abstract][Full Text] [Related]
54. [Diltiazem and drug interactions (2). Effect of co-administered diltiazem on bioavailability of propranolol]. Etoh A; Kohno K; Shimizu T Yakugaku Zasshi; 1983 Apr; 103(4):434-41. PubMed ID: 6631673 [No Abstract] [Full Text] [Related]
55. Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects. Goren MP; Houle JM; Bush DA; Li JT; Newman CE; Brade WP Clin Cancer Res; 1998 Oct; 4(10):2313-20. PubMed ID: 9796960 [TBL] [Abstract][Full Text] [Related]
56. Differences in the stereoselective pharmacokinetics of pazinaclone (DN-2327), a new anxiolytic, and its active metabolite after intravenous and oral single doses to dogs. Hussein Z; Mulford DJ; Bopp BA; Granneman GR Drug Metab Dispos; 1993; 21(5):805-10. PubMed ID: 7902240 [TBL] [Abstract][Full Text] [Related]
57. Dose-dependent bioavailability of propranolol. Kopitar Z; Vrhova B; Lenardic A; Cvelbar P; Zorz M; Francetić I Int J Clin Pharmacol Ther Toxicol; 1986 Jun; 24(6):319-22. PubMed ID: 3733282 [TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics of propranolol after single and multiple dosing with sustained release propranolol or propranolol CR (innopran XL) , a new chronotherapeutic formulation. Sica D; Frishman WH; Manowitz N Heart Dis; 2003; 5(3):176-81. PubMed ID: 12783630 [TBL] [Abstract][Full Text] [Related]
59. Influence of the route of administration on the pharmacokinetics of pirprofen enantiomers in the rat. Brocks DR; Liang WT; Jamali F Chirality; 1993; 5(2):61-4. PubMed ID: 8343343 [TBL] [Abstract][Full Text] [Related]
60. Development of a reservoir-type transdermal enantioselective-controlled delivery system for racemic propranolol using a molecularly imprinted polymer composite membrane. Suedee R; Bodhibukkana C; Tangthong N; Amnuaikit C; Kaewnopparat S; Srichana T J Control Release; 2008 Aug; 129(3):170-8. PubMed ID: 18550193 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]